Lorenza Rimassa, MD, is Associate Professor of Medical Oncology at Humanitas University and Head of HepatoPancreatoBiliary (HPB) Oncology at IRCCS Humanitas Research Hospital in Milan, Italy.

 

She is Head of External Relations and member of the Executive Committee of the International Liver Cancer Association (ILCA), Chair of the EORTC HPB/NET Tumors Task Force, holds the position of Special Expert - International Trials Europe on the HB Task Force of the NCI (US), member of the Management Committee of the COST Action CA22125 Precision-BTC-Network.

 

She is an author of the ESMO Guideline on BTC, and of the Italian Inter-Society Guideline on HCC.

 

She is PI and member of the SC/IDMC for national/international, phase 1–3 clinical/translational trials of new drugs for HPB cancers. She is speaker, chair, discussant, and member of the organizing and scientific committee at national/international congresses.

 

She has authored more than 200 articles on the development of new GI cancer treatments/biomarkers. She is Co-editor for Journal of Hepatology, Associate Editor for Liver Cancer, Section Editor-in-Chief for the Disease Biomarker Section of Journal of Personalized Medicine, and an editorial board member of several journals including JHEP Reports, Liver International, Therapeutic Advances in Medical Oncology, and Journal of Hepatocellular Carcinoma.

Assoc. Prof. Lorenza Rimassa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Agios, AstraZeneca, Basilea, Bayer, BeiGene, BMS, Eisai, Elevar Therapeutics, Exelixis, Fibrogen, Genenta, Guerbet, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, Zymeworks.